Etop Ibcsg Partners Foundation

This study tests a new approach for people with non-small cell lung cancer that has spread to a limited number of other body parts (up to 3 spots). Participants receive a combination of immunotherapy, chemotherapy, and precise radiation to the cancer spots, followed by surgery or…

This phase 3 trial tests whether adding palbociclib (Ibrance) to standard hormone therapy can delay breast cancer from returning in people whose cancer has come back in the same area. About 405 participants who have had surgery for their recurrence will receive either hormone the…

This study looks at whether young women with early-stage, hormone-sensitive breast cancer can safely pause their hormone therapy for up to two years to try to get pregnant. It involves 518 women aged 18 to 42 who have already been on hormone therapy for 18 to 30 months. The goal …

This study tests a combination of three drugs (amivantamab, lazertinib, and bevacizumab) in 60 people with advanced EGFR-mutant non-small cell lung cancer whose disease worsened after previous treatment. The goal is to see if adding two drugs to a standard targeted therapy can sh…

This study tests a daily pill called adagrasib in 68 patients with advanced lung cancer that has a specific KRAS mutation. It focuses on people aged 70 or older, or those with poor physical health, who have already tried other treatments. The goal is to see if the drug can shrink…